(Reuters) -German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 ...

BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company ...

BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key ...

A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna .

BioNTech said in a regulatory filing on Tuesday the U.S. Food and Drug Administration has placed a clinical hold on an ...

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

Half of the patients who received an experimental vaccine for pancreas cancer being developed by Roche and BioNTech following ...

Reports Q4 revenue EUR 1.19B vs. EUR 1.48B last year. “From the very beginning, BioNTech’s (BNTX) vision has been to translate our science into ...

"We expect 2025 to be a data-rich year with multiple important updates from our priority programs," said Chief Executive Ugur Sahin. BioNTech forecast revenue between 1.7 billion euros and 2.2 billion ...

The full audited consolidated financial statements as of and for the year ended December 31, 2024, can be found in BioNTech's Annual Report on Form 20-F filed today with the United States Securities ...

Freshfields has won a Düsseldorf regional court patent dispute on behalf of client Moderna against German COVID-19 vaccine ...

BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with ...